India’s biotechnology sector has achieved a significant milestone, currently valued at $150 billion. Despite this impressive figure, much of the sector’s innovation and product development potential remains untapped. Jitendra Kumar, Managing Director of the Biotechnology Industry Research Assistance Council (BIRAC), underscored the necessity for increased private-sector investment and streamlined regulatory processes to enhance India’s global standing in biotechnology during his remarks on Sunday..

印度的生物技术部门取得了一个重要的里程碑，目前价值1500亿美元。尽管这一数字令人印象深刻，但该行业的许多创新和产品开发潜力仍未开发。生物技术产业研究援助委员会（BIRAC）常务董事吉滕德拉·库马尔（JitendraKumar）在周日的讲话中强调了增加私营部门投资和简化监管程序的必要性，以提高印度在生物技术领域的全球地位。。

BIRAC’s Role and Mission

BIRAC的角色和使命

BIRAC operates as a public sector entity under the Department of Biotechnology, focusing on fostering innovation and entrepreneurship within the biotech industry. The council aims to support startups, facilitate research and development, and convert academic research into viable market products. While India is recognized for supplying 40% of the world’s generic medicines, it currently ranks only 14th globally in terms of bioeconomy value.

BIRAC是生物技术部下属的公共部门实体，专注于促进生物技术行业的创新和创业。该委员会旨在支持初创企业，促进研究和开发，并将学术研究转化为可行的市场产品。虽然印度被认为提供了世界仿制药的40%，但就生物经济价值而言，它目前在全球仅排名第14位。

This discrepancy is primarily attributed to a significant shortage of patented, innovative products that could propel India into a leadership position in the biotech landscape..

这种差异主要归因于专利创新产品的严重短缺，这可能会推动印度在生物技术领域占据领先地位。。

The Growth of Biotechnology Startups

生物技术初创公司的成长

Kumar highlighted BIRAC’s commitment to nurturing startups through various initiatives. The Promoting Academic Conversion to Enterprise (PACE) program is a prime example, designed to assist scientists in transitioning their research from laboratory settings to market-ready solutions. This program plays a crucial role in bridging the gap between academia and industry, fostering a culture of innovation that is vital for the sector’s growth..

库马尔强调了BIRAC通过各种举措培育初创企业的承诺。促进学术转化为企业（PACE）计划是一个很好的例子，旨在帮助科学家将研究从实验室环境转变为市场可用的解决方案。该计划在弥合学术界和工业界之间的差距、培养对该行业增长至关重要的创新文化方面发挥着至关重要的作用。。

Since BIRAC’s inception in 2012, the number of biotech startups in India has surged dramatically, growing from approximately 300 to over 8,000. This remarkable increase can be attributed to substantial government support, which has created a conducive environment for innovation. The bioeconomy itself has expanded from $35 billion to $150 billion over the past decade, showcasing the sector’s rapid development and potential for further growth..

自BIRAC于2012年成立以来，印度的生物技术初创公司数量急剧增加，从大约300家增加到8000多家。这一显著增长可归因于政府的大力支持，这为创新创造了有利的环境。在过去十年中，生物经济本身已从350亿美元扩大到1500亿美元，展示了该行业的快速发展和进一步增长的潜力。。

Investment and Research Challenges

投资和研究挑战

Despite these advancements, Kumar pointed out that India invests only 0.8% of its GDP in research and development (R&D), significantly lower than the over 2% invested by developed nations such as the United States and China. This gap in investment highlights the urgent need for enhanced private-sector participation in R&D efforts.

尽管取得了这些进步，库马尔指出，印度在研发方面的投资仅占其GDP的0.8%，远低于美国和中国等发达国家超过2%的投资。这种投资缺口突出表明，迫切需要加强私营部门对研发工作的参与。

By fostering a robust investment ecosystem, India can significantly boost its capacity for innovation and secure its position as a global biotech leader..

通过培育一个强大的投资生态系统，印度可以大大提高其创新能力，并确保其作为全球生物技术领导者的地位。。

Government Commitment and Future Outlook

政府承诺和未来展望

Looking ahead, Kumar expressed optimism about the future of India’s biotechnology sector. He noted that the government is increasingly committed to boosting R&D investment and aligning regulatory frameworks with global standards. These steps are seen as crucial growth drivers that will enable India to not only enhance its bioeconomy value but also improve its global competitiveness..

展望未来，库马尔对印度生物技术部门的未来表示乐观。他指出，政府越来越致力于促进研发投资，并使监管框架与全球标准接轨。这些措施被视为至关重要的增长驱动因素，将使印度不仅能够提高其生物经济价值，而且能够提高其全球竞争力。。

Kumar’s insights underscore a broader vision for the biotechnology sector in India—one where collaboration between the government, academia, and the private sector fosters an environment ripe for innovation. By prioritizing investment in research and development and facilitating smoother regulatory processes, India can unlock the full potential of its biotechnology sector and emerge as a key player on the global stage..

库马尔的见解强调了印度生物技术部门的更广泛愿景，政府，学术界和私营部门之间的合作为创新创造了成熟的环境。通过优先考虑研发投资并促进更顺畅的监管流程，印度可以充分发挥其生物技术部门的潜力，并在全球舞台上成为关键参与者。。

In conclusion, while India’s biotechnology sector is on an impressive growth trajectory, realizing its full potential will require concerted efforts from all stakeholders involved. Enhanced investment, strategic government initiatives, and a focus on innovation will be essential to elevate India’s position in the global biotechnology arena..

总之，虽然印度的生物技术部门正处于令人印象深刻的增长轨迹，但要充分发挥其潜力，需要所有相关利益相关者的共同努力。加强投资、战略性政府举措以及注重创新对于提升印度在全球生物技术领域的地位至关重要。。